AMINOSYN 3.5% M IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN 3.5% M IN PLASTIC CONTAINER (AMINOSYN 3.5% M IN PLASTIC CONTAINER).
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
| Metabolism | Amino acids are primarily metabolized in the liver via transamination, deamination, and urea cycle. Some branched-chain amino acids are metabolized in muscle. Renal excretion of ammonia and urea occurs. |
| Excretion | Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination. |
| Half-life | Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids. |
| Protein binding | Minimal (<10%) for most amino acids; weak binding to albumin and other plasma proteins. |
| Volume of Distribution | 0.2-0.4 L/kg (approximate total body water distribution); reflects rapid equilibration with extracellular and intracellular spaces. |
| Bioavailability | Intravenous: 100% (direct systemic administration). Not administered via other routes. |
| Onset of Action | Intravenous: immediate (within minutes), as amino acids are directly available for protein synthesis and metabolic processes. |
| Duration of Action | Intravenous: 2-6 hours depending on infusion rate and metabolic demands; clinical effect persists while infusion is maintained. |
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <50 mL/min: Use with caution; reduce total amino acid intake to 0.5-0.8 g/kg/day. GFR <15 mL/min: Avoid or use only with renal replacement therapy. |
| Liver impairment | Child-Pugh Class B or C: Contraindicated due to risk of hepatic encephalopathy. Use specialized hepatamine formulas if necessary. |
| Pediatric use | Weight-based: 2-3 g amino acids/kg/day for infants; 1-1.5 g/kg/day for older children. Infuse via central line for concentrations >10%. |
| Geriatric use | Start at lower end of dosing range; monitor renal function and volume status. Adjust dose based on creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN 3.5% M IN PLASTIC CONTAINER (AMINOSYN 3.5% M IN PLASTIC CONTAINER).
| Breastfeeding | Excreted in human milk in small amounts; M/P ratio not determined. Considered compatible with breastfeeding when clinically indicated. Monitor infant for gastrointestinal disturbances. |
| Teratogenic Risk | No teratogenic effects in animal studies; no adequate human studies. Use only if clearly needed. First trimester: theoretical risk from amino acid imbalances, but no evidence of harm. Second and third trimesters: essential for fetal growth; cautiously infuse to avoid hyperammonemia or acidosis. |
■ FDA Black Box Warning
Not available for this drug formulation. However, parenteral nutrition should be used with caution due to risk of metabolic complications (e.g., hyperglycemia, electrolyte imbalances) and infectious complications (catheter-related sepsis).
| Serious Effects |
["Severe renal impairment (anuria, acute renal failure) without appropriate adjustments","Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria) unless specifically formulated","Severe liver failure with hyperammonemia","Hypersensitivity to any component"]
| Precautions | ["Risk of fluid overload in patients with renal or cardiac impairment","Monitor serum electrolytes, blood glucose, and nitrogen balance regularly","Potential for metabolic acidosis with high chloride content","Use with caution in hepatic encephalopathy due to potential ammonia elevation","Risk of vein irritation or thrombophlebitis with peripheral administration"] |
| Food/Dietary | No direct food interactions as this is administered intravenously. However, oral intake may need to be coordinated to avoid excessive protein load. In patients with renal impairment, protein intake from all sources should be considered. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal and fetal vital signs, serum electrolytes, acid-base status, ammonia, and glucose. Assess for signs of fluid overload, hyperammonemia, and metabolic acidosis. Fetal surveillance as per obstetric indications. |
| Fertility Effects | No known effects on human fertility. Not studied. No evidence of reproductive toxicity in animal studies. |
| Clinical Pearls | AMINOSYN 3.5% M is a parenteral amino acid solution for intravenous infusion. It should be administered via central line due to osmolarity >900 mOsm/L. Monitor serum electrolytes, BUN, and glucose regularly. Do not use if protein metabolism is severely impaired (e.g., hepatic coma). Ensure adequate non-protein calories are provided to promote protein synthesis. Infusion rate should not exceed 100 mL/hour initially. Note: Contains electrolytes; adjust other electrolyte sources accordingly. |
| Patient Advice | This medication is given through a vein (IV) to provide protein for your body. · Report any signs of infection at the IV site such as redness, swelling, or pain. · Tell your healthcare provider if you have diabetes or kidney/liver problems. · You may need regular blood tests to monitor your nutrition and organ function. · Do not suddenly stop this medication without consulting your provider. |